The double-blind, placebo-controlled and randomized trial which enrolled 100 patients was designed to assess the efficacy and safety of the talactoferrin in patients with previously treated non-small cell lung cancer (NSCLC).
The study, conducted in patients with NSCLC for whom one or more prior lines of anti-cancer therapy had failed achieved its primary endpoint of improvement in overall survival.
Supportive results were seen in the secondary endpoints of progression-free survival and disease control rate.
Agennix chief medical officer Rajesh Malik said they look forward to report topline results from their ongoing Phase III Fortis-M registration trial in advanced non-small cell lung cancer in the first half of 2012.